Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030187 | 0.90 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3023336 | 0.85 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3022448 | 0.85 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3018957 | 0.85 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3017255 | 0.81 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8141108 | 0.81 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3017751 | 0.79 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3029328 | 0.79 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3023365 | 0.78 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3023919 | 0.77 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| EP-2121633-A2 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099210-A2 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099210-A2 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | PSEN1, PSEN2, APP | PSEN1 1/4885PSEN2 2/4885APH1B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.